Early Signs of Alzheimer’s Disease Found in Groundbreaking Brain Study
Researchers from the University of Aberdeen have made a significant advance in understanding the early signs of Alzheimer’s disease. For the first time, scientists confirmed that two proteins long associated with the condition are both present at the very earliest stages of the disease, appearing together in the same brain region involved in memory formation and information processing.
The study, funded by Alzheimer’s Research UK, used human brain tissue from the Brains for Dementia Research platform to examine changes across different stages of Alzheimer’s progression. The findings, published in the journal Acta Neuropathologica, carry important implications for both drug development and diagnostic procedures.
The Two Proteins at the Center of Alzheimer’s Research
For decades, the scientific debate around Alzheimer’s disease has centered on two proteins: tau and amyloid. Both have been identified as key contributors to the neurodegeneration that defines the condition, but researchers had long believed they emerged in separate brain regions at different points in the disease timeline.
This new research challenges that assumption entirely. The team, led by Dr. David Koss and Professor Bettina Platt, developed novel methods to study both proteins simultaneously and found that they appear together in the same brain area at very early stages, before the formation of the plaques and tangles typically associated with Alzheimer’s.
Professor Bettina Platt commented that the relationship between tau and amyloid had never previously been demonstrated in human cases, and that the findings consolidate conflicting evidence from earlier studies. The discovery strongly supports the idea that these two proteins interact with each other from the very beginning of the disease process, rather than operating independently.
Why Early Detection of Alzheimer’s Matters
One of the most persistent challenges in Alzheimer’s research is that by the time symptoms become apparent, significant neurological damage has already occurred. Identifying the early signs of Alzheimer’s disease before symptoms emerge is considered essential for improving treatment outcomes and developing more effective interventions.
Professor Platt noted that Alzheimer’s related changes in the brain are widely believed to begin long before a patient notices any cognitive symptoms, but reliable methods to detect those changes had remained elusive. The new methodology developed by her team allows researchers to determine precisely when and where these proteins appear, establishing what she described as a new benchmark for pathological investigations.
Dr. Koss added that the findings highlight specific biochemical processes that may enable improved diagnostic procedures and inform future drug development programs. The ability to detect both proteins together at an early stage opens new possibilities for designing targeted therapies aimed at interrupting the disease before it progresses.
Implications for Drug Development and Diagnosis
Dr. Rosa Sancho, Head of Research at Alzheimer’s Research UK, highlighted that understanding which specific forms of tau and amyloid drive the earliest stages of the disease will allow scientists to design drugs that target those forms directly. It also opens pathways to developing more accurate and earlier diagnostic tools.
This kind of foundational research is precisely what makes clinical trials in neurology so critical. Without a clear understanding of disease mechanisms at the molecular level, the development of treatments that can meaningfully alter disease progression remains out of reach. For more on how Alzheimer’s disease develops and its known risk factors, the Mayo Clinic provides a thorough patient friendly overview.
The Role of Clinical Research in Fighting Alzheimer’s Disease
Translating discoveries like this one into real world treatments requires robust clinical infrastructure. FOMAT supports the advancement of neurological research through participation in Phase I through Phase IV studies across a national network of investigator sites.
If you or someone you know is interested in participating in a clinical study, visit our patient active studies page to learn about current opportunities. For more research and health insights, explore the FOMAT blogs and updates.